Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO)
dosed once daily for 5 days is a safe treatment for patients who have suffered an acute
ischemic stroke.